Global Health (Medanta) Q2 FY27 revenue up 33.6%; 500-bed Ghaziabad hospital approved
Global Health · Healthcare Services
Key highlights
- Q2 FY27 revenue from operations INR 14,690 million, up 33.6% y-o-y; H1 FY27 INR 27,731 million, up 30.2% y-o-y
- Q2 FY27 Operating EBITDA INR 3,701 million, up 60.2% y-o-y; Q2 FY27 profit after tax INR 2,191 million, up 38.3% y-o-y
- Board approved a 500-bed super-speciality hospital in Ghaziabad; 2.61-acre plot allotted through e-auction for INR 1,658.2 million, estimated capex approx. INR 9,970 million
Why it's rated notable: the year-on-year change is 38% (20% to 50%)
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Other capex / expansion filings this fortnight
- ZF Steering Gear (India) reports unaudited Q2 and H1 results ended Sept 30, 2026
- Balaji Amines reports Q2 FY27 consolidated revenue of ₹472 crore and PAT of ₹67 crore
- ACME Solar commissions additional 66.68 MW solar capacity in Rajasthan
- AELEA Commodities Ltd announces Q2 financials, director changes, and business plans
- Lehar Footwears Q2FY27 revenue ₹100.1 crore vs ₹140.5 crore; PAT ₹4.6 crore vs ₹7.3 crore
- Shera Energy reports highest-ever H1FY27 revenue of ₹1047.4 Cr and PAT of ₹30.77 Cr
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM Quality Care LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.